| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c406f53b118a3aebc9af677163fd02dc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f8c0982b0f02b1ed6d20a315370a3a3a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cb89e755ca7d80d8ceac86d3aa231cf4 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16122
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16134 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-564
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-005 |
| filingDate |
2015-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f6dde2179ea500f38017c74dbf0465f7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ddac4a6d9c9814c9c0f1551f3dc6ab93
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_85e41130491f783773736984e99c9089
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ec24ed90e1f19ac8b693d10aec9ee8b9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_936947913295bd15e06a58b9bac77e3f |
| publicationDate |
2016-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2016185825-A1 |
| titleOfInvention |
Engineered outer domain (eod) of hiv gp120 and mutants thereof |
| abstract |
The invention relates to an engineered outer domain (eOD) of HIV gp120 and mutants thereof and methods of making and using the same. The mutant eODs may be advantageous for the elicitation of CD4-binding site (CD4bs)-directed broadly-neutralizing antibodies (bnAbs) and/or improve binding to mature VRC01 and/or improve binding to germline VRC01 and the germlines of other VH1-2 derived broadly-neutralizing antibodies. The mutant eODs may also include glycan-masking mutations on eOD. The present invention also includes fusions of eOD to various protein multimers to enhance immunogenicity as well as the design of cocktails of different eODs that represent the full diversity of HIV sequences within the VRC01 epitope and surroundings. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019126371-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11344618-B2 |
| priorityDate |
2011-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |